Zheng Quan Shi Bao Wang·2026-01-05 08:59Group 1 - The cell immunotherapy concept increased by 4.73%, ranking 7th among concept sectors, with 56 stocks rising, including Guanhao Biological reaching a 20% limit up [1] - Notable gainers in the sector include International Medicine, Saily Medical, and Zhaoyan New Drug, all hitting the limit up, while stocks like Saifutian and *ST Biology experienced declines [1][2] - The cell immunotherapy sector saw a net inflow of 1.058 billion yuan, with 38 stocks receiving net inflows, and Zhaoyan New Drug leading with a net inflow of 232 million yuan [2][3] Group 2 - The top stocks by net inflow ratio include Saily Medical at 57.96%, International Medicine at 41.60%, and Zhaoyan New Drug at 22.45% [3] - The trading performance of key stocks shows Zhaoyan New Drug and Saily Medical both achieving over 10% gains, while Guanhao Biological reached a 20% increase [3][4] - Other notable performers include Bibeite and Yuekang Pharmaceutical, with increases of 11.84% and 10.13% respectively [1][5]